[go: up one dir, main page]

MX2016014989A - Derivados antibacterianos de quinazolina-4 (3h)-ona. - Google Patents

Derivados antibacterianos de quinazolina-4 (3h)-ona.

Info

Publication number
MX2016014989A
MX2016014989A MX2016014989A MX2016014989A MX2016014989A MX 2016014989 A MX2016014989 A MX 2016014989A MX 2016014989 A MX2016014989 A MX 2016014989A MX 2016014989 A MX2016014989 A MX 2016014989A MX 2016014989 A MX2016014989 A MX 2016014989A
Authority
MX
Mexico
Prior art keywords
halogen
derivatives
antibacterial
cycloprop
morpholin
Prior art date
Application number
MX2016014989A
Other languages
English (en)
Inventor
Christophe Gauvin Jean-
Mirre Azely
CHAPOUX Gaëlle
Philippe Surivet Jean-
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of MX2016014989A publication Critical patent/MX2016014989A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La invención se refiere a compuestos antibacterianos de fórmula I, donde R1 es H o halógeno; R2 es el grupo M; R3 es H o halógeno; M es MA o MB, donde A es un enlace o C=C; R1A es H o halógeno; R2A es H, alcoxi o halógeno; R3A es H, alcoxi, hidroxialcoxi, hidroxialquilo, 1,2-dihidroxietilo, dialquilamino, 1-hidroximetil-cicloprop-1-ilo, 1-((dimetilglicil)oxi)metil-ciclop rop-1-ilo, 3-hidroxioxetan-3-ilo, morfolin-4-ilalquilo o morfolin-4-ilalcoxi; y R1B es un grupo tal como se definió en la reivindicación 1; y sus sales. (ver Fórmulas).
MX2016014989A 2014-05-16 2015-05-13 Derivados antibacterianos de quinazolina-4 (3h)-ona. MX2016014989A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14168718 2014-05-16
PCT/EP2015/060653 WO2015173329A1 (en) 2014-05-16 2015-05-13 Antibacterial quinazoline-4(3h)-one derivatives

Publications (1)

Publication Number Publication Date
MX2016014989A true MX2016014989A (es) 2017-03-31

Family

ID=50731968

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016014989A MX2016014989A (es) 2014-05-16 2015-05-13 Derivados antibacterianos de quinazolina-4 (3h)-ona.

Country Status (19)

Country Link
US (1) US9796686B2 (es)
EP (1) EP3143007B1 (es)
JP (1) JP2017515906A (es)
KR (1) KR20170005105A (es)
CN (1) CN106458931A (es)
AR (1) AR100428A1 (es)
AU (1) AU2015261540A1 (es)
BR (1) BR112016026787A8 (es)
CA (1) CA2948077A1 (es)
CL (1) CL2016002918A1 (es)
EA (1) EA201692305A1 (es)
ES (1) ES2687040T3 (es)
IL (1) IL248922A0 (es)
MX (1) MX2016014989A (es)
PH (1) PH12016502253A1 (es)
SG (1) SG11201609286VA (es)
TW (1) TW201625559A (es)
WO (1) WO2015173329A1 (es)
ZA (1) ZA201608680B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR097617A1 (es) 2013-09-13 2016-04-06 Actelion Pharmaceuticals Ltd Derivados antibacterianos del 2h-indazol
US9624206B2 (en) 2013-12-19 2017-04-18 Actelion Pharmaceuticals Ltd Antibacterial 1H-indazole and 1H-indole derivatives
AR099612A1 (es) 2014-03-04 2016-08-03 Actelion Pharmaceuticals Ltd Derivados antibacterianos de 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona
AR105646A1 (es) 2015-08-11 2017-10-25 Actelion Pharmaceuticals Ltd Agentes antibacterianos de 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona sustituida
US20190031676A1 (en) * 2015-08-28 2019-01-31 Idorsia Pharmaceuticals Ltd Antibacterial annulated pyrrolidin-2-one derivatives
AR105889A1 (es) 2015-09-03 2017-11-22 Actelion Pharmaceuticals Ltd Compuestos antibacterianos 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona sustituidos
US10781184B2 (en) 2015-12-08 2020-09-22 Glaxosmithkline Intellectual Property Development Limited Substituted benzazinones as antibacterial compounds
CA3017388C (en) 2016-04-01 2024-03-12 Zeno Royalties & Milestones, LLC Estrogen receptor modulators
CN110088087B (zh) * 2016-09-28 2022-08-09 东亚St株式会社 四氢吡啶衍生物及其作为抗菌剂的用途
EP3993787A4 (en) 2019-08-06 2023-07-12 Recurium IP Holdings, LLC Estrogen receptor modulators for treating mutants

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE263554T1 (de) 1997-02-27 2004-04-15 Wyeth Corp N-hydroxy-2-(alkyl, aryl oder heteroaryl sulfanyl,sulfinyl oder sulfonyl)-3-substituierte alkyl-, aryl- oder heteroarylamide als matrixmetalloproteinaseinhibitoren
WO2003077914A1 (en) 2002-03-13 2003-09-25 Array Biopharma, Inc N3 alkylated benzimidazole derivatives as mek inhibitors
CA2691987C (en) * 2007-06-12 2016-08-16 Achaogen, Inc. Antibacterial agents
WO2010024356A1 (ja) 2008-08-27 2010-03-04 大正製薬株式会社 ナフチリジン－ｎ－オキシドを有する新規ヒドロキサム酸誘導体
EP2350039A4 (en) 2008-10-03 2012-10-10 Boehringer Ingelheim Int INHIBITORS OF VIRAL POLYMERASE
DE102008044132A1 (de) 2008-11-27 2010-06-02 BSH Bosch und Siemens Hausgeräte GmbH Kältegerät mit zweiseitig anschlagbarer Tür
EP2432468A2 (en) 2009-05-20 2012-03-28 Ardea Biosciences, Inc. Methods of modulating uric acid levels
EP2488489A2 (en) 2009-10-13 2012-08-22 Pfizer Inc. C-linked hydroxamic acid derivatives useful as antibacterial agents
US8664401B2 (en) * 2009-12-16 2014-03-04 Pfizer Inc. N-linked hydroxamic acid derivatives useful as antibacterial agents
WO2012054332A1 (en) 2010-10-18 2012-04-26 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
EP2638006A1 (en) 2010-11-10 2013-09-18 Achaogen, Inc. Hydroxamic acid derivatives and their use in the treatment of bacterial infections
EP2661438A4 (en) 2011-01-03 2014-06-11 Hanmi Pharm Ind Co Ltd NEW BICYCLIC COMPOUND FOR MODULATING G-PROTEIN-COUPLED RECEPTORS
MA34963B1 (fr) * 2011-03-07 2014-03-01 Pfizer Derives de fluoro-pyridinone utiles en tant qu'agents antibacteriens
CA2830866A1 (en) 2011-04-08 2012-10-11 Pfizer Inc. Imidazole, pyrazole, and triazole derivatives useful as antibacterial agents
JP2014510132A (ja) 2011-04-08 2014-04-24 ファイザー・インク 抗菌剤として有用なイソオキサゾール誘導体
AU2012267622B2 (en) 2011-06-08 2017-06-22 Sunovion Pharmaceuticals, Inc. Metabotropic glutamate receptor 5 modulators and methods of use thereof
EP2847162A1 (en) 2012-05-09 2015-03-18 Achaogen, Inc. Antibacterial agents
EP2847168A1 (en) * 2012-05-10 2015-03-18 Achaogen, Inc. Antibacterial agents
WO2015024010A2 (en) 2013-08-16 2015-02-19 Duke University Substituted hydroxamic acid compounds
AR097617A1 (es) 2013-09-13 2016-04-06 Actelion Pharmaceuticals Ltd Derivados antibacterianos del 2h-indazol
US9624206B2 (en) 2013-12-19 2017-04-18 Actelion Pharmaceuticals Ltd Antibacterial 1H-indazole and 1H-indole derivatives
AR099612A1 (es) 2014-03-04 2016-08-03 Actelion Pharmaceuticals Ltd Derivados antibacterianos de 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona

Also Published As

Publication number Publication date
TW201625559A (zh) 2016-07-16
KR20170005105A (ko) 2017-01-11
US9796686B2 (en) 2017-10-24
BR112016026787A8 (pt) 2017-12-26
EP3143007B1 (en) 2018-07-11
SG11201609286VA (en) 2016-12-29
PH12016502253A1 (en) 2017-01-16
EA201692305A1 (ru) 2017-05-31
CN106458931A (zh) 2017-02-22
AU2015261540A1 (en) 2017-01-12
CL2016002918A1 (es) 2017-04-07
ZA201608680B (en) 2018-11-28
BR112016026787A2 (es) 2017-08-15
EP3143007A1 (en) 2017-03-22
JP2017515906A (ja) 2017-06-15
US20170081292A1 (en) 2017-03-23
AR100428A1 (es) 2016-10-05
CA2948077A1 (en) 2015-11-19
ES2687040T3 (es) 2018-10-23
IL248922A0 (en) 2017-01-31
WO2015173329A1 (en) 2015-11-19

Similar Documents

Publication Publication Date Title
PH12016502253A1 (en) Antibacterial quinazoline-4(3h)-one derivatives
PH12016501535A1 (en) Uracil derivatives as axl and c-met kinase inhibitors
MX2016003196A (es) Derivados antibacterianos del 2h-indazol.
DOP2015000251A (es) Derivados de naftiridina utiles como antagonistas de la alfa-v-beta-6 integrina
MD4531B1 (ro) Derivaţi ai benzimidazolonei în calitate de inhibitori ai bromodomeniului
MX374729B (es) Compuestos de heteroarilo o arilo biciclicos fusionados y su uso como inhibidores irak4.
PH12015502534A1 (en) Benzimidazole derivatives as bromodomain inhibitors
JO3261B1 (ar) مشتق بيريدين أحادي الحلقة
MX2017003930A (es) Derivados de aminotriazina utiles como compuestos inhibidores de la cinasa de union a tank.
MX368066B (es) Derivados de quinazolin-4-ona sustituida.
CR20150470A (es) Derivados de triazolona de piridinilo y piridinilo fusionado
MY180751A (en) 3,4-dihydroisoquinolin-2(1h)-yl compounds
MX2016011380A (es) Derivados de 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona y su uso como agentes antibacterianos.
MX360983B (es) Derivados antibacterianos de 1h-indazol y 1h-indol.
TW201613904A (en) Pyridone derivatives containing tetrahydropyranylmethyl group
JO3318B1 (ar) مثبطات bace
MX389265B (es) Aminopirimidinas como inhibidores de alk.
MD20150103A2 (ro) Derivaţi ai imidazo-triazinei ca inhibitori ai PDE10
PH12017500907A1 (en) Antibacterial benzothiazole derivatives
MX2018002479A (es) Derivados antibacterianos pirrolidin-2-ona anulados.
EA201391793A1 (ru) Новый способ синтеза 7-хлор-4-(пиперазин-1-ил)-хинолина
MX373441B (es) Derivados de indol-urea glucopiranosil-sustituido y su uso como inhibidores sglt.
NZ590367A (en) 9-Substituted-5-carboxy-oxadiazino-quinolone derivatives, their preparation and their application as anti-bacterials
PL408801A1 (pl) Nowe 5-arylo-7-metylo-5H-pirazolo[4,3-e]tetrazolo[4,5-b][1,2,4]triazyny
EA201400882A1 (ru) Способ стереоселективного синтеза 9-гидрокси-5-оксо-1,4-диазаспиро[5.5]ундеканов, содержащих защитные группы в 1,4-положениях